Abivax May List on Nasdaq After U.S. Lifts Cuba Embargo
This article is for subscribers only.
Abivax SA, a French biotechnology company that listed on the Euronext stock exchange in Paris last week, may offer shares in the U.S. after the embargo on Cuba is lifted, Chief Executive Officer Hartmut Ehrlich said.
Abivax’s experimental ABX203 treatment for hepatitis B was acquired from the Center for Genetic Engineering and Biotechnology in Cuba, which makes a U.S. Nasdaq listing “difficult” while the embargo is still in place, Ehrlich said in a phone interview on Tuesday.